Botechnology company Ridgeback Biotherapeutics LP said on Wednesday that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its investigational Ebola treatment, ansuvimab (mAb114), and granted priority review designation.
Ansuvimab is a monoclonal antibody isolated from a human survivor of the 1995 Ebola outbreak in Kikwit, Democratic Republic of the Congo.
According to Wendy Holman, CEO and co-founder of Ridgeback, the treatment has demonstrated "an impressive survival benefit" in Ebola patients.
The FDA previously granted Breakthrough Therapy Designation status to ansuvimab as a treatment for Ebola in September 2019.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval